Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential

The FDA has approved remdesivir for use against SARS-CoV-2, though initial reports indicated its effectiveness in humans was below 10% despite strong performance in laboratory cell cultures. Researchers have identified the drug’s instability in the presence of plasma as a key factor limiting its impact.

Addressing Remdesivir’s Limitations

To improve remdesivir’s effectiveness, two approaches were taken. The first involved creating a derivative of remdesivir called remdesivir bis-propionate (remdesivir-bP). The second utilized a biopolymer, NV387, designed to protect the remdesivir compound from degradation when exposed to plasma.

Did You Know? Remdesivir demonstrated effectiveness against SARS-CoV-2 in cell culture systems, but this did not fully translate to human trials.

Research Findings

Results indicate that remdesivir-bP is more stable in vivo compared to remdesivir alone. Further enhancement of stability was achieved when remdesivir-bP was encapsulated within the NV387 biopolymer. Antiviral activity against NL-63 infection in a rat model was also increased using both encapsulated and derivative forms of the drug, compared to remdesivir alone.

Expert Insight: The research highlights the challenges of translating promising laboratory results into effective treatments for viral infections, emphasizing the importance of addressing drug stability and delivery mechanisms.

The antiviral efficacy of the remdesivir pro-drug can be summarized as follows: remdesivir-bP-encapsulated > remdesivir-encapsulated > remdesivir-bP > remdesivir.

What Could Happen Next

Further research could explore the long-term stability and efficacy of remdesivir-bP and the NV387 encapsulation method in larger clinical trials. These advancements could lead to improved treatment protocols for SARS-CoV-2 infections. Analysts expect continued investigation into methods to enhance drug delivery and overcome the challenges of viral mutation.

Frequently Asked Questions

What is remdesivir-bP?

Remdesivir-bP is a derivative of remdesivir created to improve its stability and effectiveness.

What is NV387?

NV387 is a biopolymer designed to protect remdesivir from degradation in plasma.

How was antiviral efficacy measured?

Antiviral efficacy was measured against NL-63 infection in a rat model, comparing remdesivir alone, remdesivir-bP, encapsulated remdesivir, and remdesivir-bP encapsulated within NV387.

How might advancements in drug delivery systems impact the future of antiviral treatments?